Beyond Viruses and Bacteria: The Race for the First Fungal Vaccine and Its Promise for the Vulnerable
UGA developed a pan-fungal vaccine (NXT-2) targeting Aspergillus, Candida, and Pneumocystis, responsible for over 80% of fatal fungal infections. Aims to protect immunocompromised patients, starting with clinical trials against recurrent yeast infections.
Share